Aug 8, 2025, 06:16
Accelerating Cancer Drug Development with AI: Interview with Dr. Jen-Tang (JT) Lu from Vysioneer
In this episode, Dr. Jen-Tang (JT) Lu, Co-founder and CEO of Vysioneer, is interviewed by Emma Ter-Azaryan, YouTube Content Coordinator of OncoDaily. Dr. Lu shares his journey developing FDA-cleared AI to accelerate oncology clinical trials and deliver effective treatments to patients faster.
Vysioneer is an oncology-focused AI company pioneering regulatory-grade solutions to transform how drug efficacy is evaluated in clinical development.
Key topics discussed:
- Building FDA-cleared, regulatory-grade AI and becoming the first to deploy AI in pharma-sponsored prospective trials for efficacy evaluation
- Using AI to achieve what humans can do (e.g., automating RECIST) and go beyond human capabilities (e.g., predicting PFS/OS)
- Founding and leading a mission-driven, patient-centered AI company
- Strategic collaborations with pharmaceutical companies and leading academic institutions
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 05:47
Aug 8, 2025, 05:01
Aug 7, 2025, 21:48